on GENFIT (EPA:GNFT)
GENFIT Releases 2025 Universal Registration Document
GENFIT, a biopharmaceutical company specializing in rare liver diseases, has announced the filing of its 2025 Universal Registration Document with the Autorité des marchés financiers. The document is freely accessible on GENFIT's and AMF's websites. It comprises essential reports, including the annual financial and management reports, and auditors’ summaries.
GENFIT's focus remains on advancing treatments for acute liver failure and related conditions. The company has established a broad R&D portfolio to address unmet medical needs in liver diseases. Notably, GENFIT received accelerated approval for Iqirvo® in 2024, which is now marketed in various countries.
The firm's commitment to innovation continues with its diagnostic solutions, reinforcing its position in developing effective therapies and diagnostics for challenging medical conditions.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all GENFIT news